Investment House 13F: Cuts EW Stake by $5.4M

An institutional investor cut its holdings in Edwards Lifesciences Corporation EW by 52.3% during the quarter, according to a Form 13F filed with the SEC on October 21, 2026. The stock closed at $88.40 on the day of the filing.

EW Edwards Lifesciences Corporation

$89.37 ▲ +4.73% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Investment House's Edwards Lifesciences Position

The fund trimmed its stake by 62,285 shares during the period, bringing its total down to 56,715 shares. That remaining position carried an estimated value of $4.89 million at the time of the filing, following the reduction from its previous total of 119,000 shares.

Other Institutional Activity in Edwards Lifesciences

Assenagon Asset Management S.A. reduced its holdings by 1,020,584 shares, ending with 1,265,714 shares worth about $114.90 million. Bank Of New York Mellon Corporation trimmed its stake by 2,652,871 shares, leaving it with 14,084,483 shares valued at roughly $1.25 billion. Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main grew its holdings by 190,900 shares, ending with 13,002,965 shares worth about $1.15 billion. Ninety One UK Ltd cut its stake by 393,558 shares, closing out the period with 11,943,675 shares valued at approximately $1.06 billion.

Edwards Lifesciences Corporation Stock Up 0.6%

Edwards Lifesciences shares recently traded around $88.97 as of October 22, 2026, up about 0.6% from the filing date close. The stock has moved between a 52-week low of $74.66 and a high of $96.29, sitting above both its 50-day moving average of $88.19 and its 200-day moving average of $85.19.

Recent Earnings

The medical technology firm reported trailing twelve month revenue of $6.51 billion alongside basic earnings per share of $1.68. The company posts a net profit margin of 15.4% and a return on equity of 9.2%, with its next financial results scheduled for release on November 4, 2026.

Insider Buying and Selling at Edwards Lifesciences Corporation

Corporate insiders have transacted in the stock across multiple recent dates, including executive moves by Daniel Lippis and Andrew M Dahl involving smaller block purchases and sales.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock in recent months, with JP Morgan, Piper Sandler, Leerink Partners, BTIG, and Barclays maintaining or establishing ratings alongside price targets ranging from $101.00 to $110.00. Analysts maintain a consensus buy rating on the stock with a mean price target of $101.81 across 26 analyst opinions.

About Edwards Lifesciences

Edwards Lifesciences Corporation makes specialized medical devices and technologies used to treat advanced cardiovascular diseases. Its primary product lines include transcatheter heart valve replacement systems like the SAPIEN family, alongside repair and replacement products for mitral and tricuspid valves sold under the PASCAL and EVOQUE brands.

Bottom Line

The recent institutional filing highlights shifting sentiment among large investors as the healthcare company approaches its upcoming earnings report in November. Market participants continue to monitor institutional rebalancing alongside ongoing analyst price targets for the medical device provider.